Transcode Therapeutics

Transcode Therapeutics Revenue

The revenue of Transcode Therapeutics (RNAZ) as of Oct 18, 2026.

Revenue

0.00USD

Last updated:

In 2025, Transcode Therapeutics's sales reached 0.00 USD, a % difference from the 0.00 USD sales recorded in the previous year.

The Transcode Therapeutics Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
Date
Revenue
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD
Jan 1, 2026 (e)
0.00 USD
Jan 1, 2027 (e)
0.00 USD
Jan 1, 2028 (e)
10.10 M USD
Jan 1, 2029 (e)
28.36 M USD
Jan 1, 2030 (e)
52.94 M USD
The Transcode Therapeutics Revenue history
YEARRevenueYoY
est52.94 MUSD+86.69%
est28.36 MUSD+180.81%
est10.10 MUSD—
est0.00USD—
est0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transcode Therapeutics Revenue

Transcode Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-19.42 M USD
-18.55 M USD
Jan 1, 2024
0.00 USD
-16.73 M USD
-16.75 M USD
Jan 1, 2025
0.00 USD
-27.98 M USD
-34.66 M USD
Jan 1, 2026 (e)
0.00 USD
-16.73 M USD
-294,400.00 USD
Jan 1, 2027 (e)
0.00 USD
-23.36 M USD
-225,216.00 USD
Jan 1, 2028 (e)
10.10 M USD
-26.72 M USD
-581,808.00 USD
Jan 1, 2029 (e)
28.36 M USD
-25.09 M USD
-544,272.00 USD
Jan 1, 2030 (e)
52.94 M USD
0.00 USD
-319,056.00 USD

Transcode Therapeutics Margins

Transcode Therapeutics stock margins

The Transcode Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Transcode Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Transcode Therapeutics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
- %
- %
Jan 1, 2027 (e)
0.00 %
- %
- %
Jan 1, 2028 (e)
0.00 %
-264.65 %
-5.76 %
Jan 1, 2029 (e)
0.00 %
-88.49 %
-1.92 %
Jan 1, 2030 (e)
0.00 %
0.00 %
-0.60 %

Transcode Therapeutics Stock analysis

What does Transcode Therapeutics do? Transcode Therapeutics Inc is a biotechnology company headquartered in Boston, Massachusetts, operating within the health care sector. The firm specializes in the development and commercialization of diagnostic tools and therapeutic agents aimed at the detection and treatment of cancer. As of the latest available data, the organization employs nineteen full-time staff members, reflecting its position as a focused entity in the competitive biopharmaceutical landscape. The company made its public debut on the stock market on April 28, 2021, under the ticker symbol RNAZ, with an International Securities Identification Number of US89357L5012. Its strategic focus is heavily anchored in RNA-based technologies and novel mechanisms to combat malignancies across various tissue types. The company’s lead therapeutic candidate, TTX-MC138, is designed to target microRNA-10b, a critical regulator of metastatic cell viability. This target is implicated in a wide spectrum of cancers, including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas and other solid tumors. By addressing this specific molecular pathway, Transcode Therapeutics aims to inhibit the spread and survival of cancer cells. In addition to its lead candidate, the firm maintains a robust pipeline of preclinical programs that explore diverse therapeutic modalities. One such program is TTX-siPDL1, which utilizes small interfering RNA to modulate programmed death-ligand 1, a protein often exploited by tumors to evade the immune system. Another preclinical initiative, TTX-siLIN28B, employs siRNA technology to inhibit the RNA-binding protein LIN28B, further expanding the company’s approach to gene silencing. Beyond solid tumor targets, Transcode Therapeutics is developing indication-agnostic programs that seek to activate the body’s natural defenses against cancer. TTX-RIGA is an RNA-based agonist of the retinoic acid-inducible gene I, designed to trigger innate immunity within the tumor microenvironment. The company also explores advanced genetic editing through TTX-CRISPR, a platform based on CRISPR/Cas9 technology intended to repair or eliminate cancer-causing genes directly within tumor cells. Furthermore, the firm is working on TTX-mRNA, a tumor-type specific platform for developing cancer vaccines. These vaccines are engineered to activate cytotoxic immune responses, thereby enhancing the body’s ability to recognize and destroy malignant cells. Through this multi-faceted approach combining diagnostics, therapeutics, and immune activation, Transcode Therapeutics Inc strives to provide innovative solutions for patients with various forms of cancer. Transcode Therapeutics is one of the most popular companies on Eulerpool.

Revenue Details

Understanding Transcode Therapeutics's Sales Figures

The sales figures of Transcode Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Transcode Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Transcode Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Transcode Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Transcode Therapeutics stock

On Eulerpool you can find the complete historical development of The revenue Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Revenue is the total value of all goods sold in a period. It is calculated by multiplying the quantity of each product sold by its selling price. Revenue does not include any costs (material costs, personnel costs, etc.), whereas net proceeds only deduct revenue reductions associated with the sale (discounts, etc.).

The revenue's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The revenue's Transcode Therapeutics historically and in real time.

The revenue in assessing a stock

Revenue is an important financial measure used in the valuation of stocks. It is a measure of a company's economic activity and can serve as an indicator of the company's success. Revenue is considered one of the most important factors in stock valuation. In addition, revenue can also be used to calculate other financial measures such as earnings per share and price-earnings ratio.

History and utilization of revenue

Revenue has long been considered one of the most important financial indicators. It was used in the 19th century as one of the first financial indicators to measure a company's economic activity. Since then, revenue has been regularly used to evaluate companies.

Revenue is usually calculated as a percentage of the company's equity. It can also be used to determine the overall profitability of a company. There are many different types of revenue that can be used to measure a company's economic activity, such as gross revenue, net revenue, and revenue from international business.

The revenue can also be used to evaluate stocks. For example, the revenue of a company can be used to evaluate the success of the company. If a company has high revenue, it means that it is a profitable company because it has high demand for its products or services.

Calculation and Application of Revenue

In order to calculate a company's revenue, the company's income must be deducted from its expenses. The income can come from various sources, such as sales, licensing fees, services, etc. The expenses can include costs for production, procurement, inventory, sales, and administration.

The revenue can then be used to calculate various financial ratios. For example, the revenue can be used to calculate the price-earnings ratio (P/E ratio) of a company. This is a measure of a company's profitability, calculated by taking the ratio of the stock price to earnings per share.

Revenue can also be used to calculate earnings per share (EPS) of a company. This is a measure of a company's profit per share. EPS is calculated by dividing earnings by the number of shares issued.

Use of revenue by investors

Investors use revenue to evaluate stocks, as revenue is an indicator of a company's success. For example, an investor can compare a company's revenue to see how successful it is. An investor can also use a company's revenue to calculate its price-to-earnings ratio and earnings per share.

An example: An investor looks at a company that has a revenue of 25 million euros. He compares this revenue to that of the competitor, which has a revenue of 35 million euros. The investor can then see that the company with 25 million euros in revenue is less successful than the company with 35 million euros in revenue.

Advantages and Disadvantages of Revenue.

Revenue is a very useful tool for valuing stocks as it measures a company's economic activity. Revenue can also be used to calculate other financial ratios such as the price-earnings ratio and earnings per share.

However, one disadvantage is that revenue alone is not a meaningful indicator of a company's success. It is important to consider revenue in comparison to other financial metrics such as earnings per share and price-to-earnings ratio to get a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Transcode Therapeutics

All Key Metrics — Transcode Therapeutics